Foghorn Therapeutics (FHTX) Cash from Operations (2019 - 2026)

Foghorn Therapeutics' Cash from Operations history runs 8 years deep, the most recent figure standing at 25266000.0 for Q1 2026.

• On a quarterly basis, Cash from Operations fell 5.42% year-over-year to 25266000.0 in Q1 2026; TTM through Mar 2026 was 87397000.0, a 8.03% increase from a year earlier, with the FY2025 full-year figure at 86099000.0, up 14.25% from the prior year.
• Cash from Operations retreated to 25266000.0 in Q1 2026 per FHTX's latest filing, from 22271000.0 in the prior quarter.
• Across five years, Cash from Operations topped out at 271534000.0 in Q1 2022 and bottomed at 32175000.0 in Q2 2023.
• The 5-year median for Cash from Operations is 25266000.0 (2026), against an average of 8015588.24.
• Biggest YoY gain for Cash from Operations was 1273.09% in 2022; the steepest drop was 343.43% in 2022.
• Year by year, Cash from Operations stood at 28924000.0 in 2022, then advanced by 4.78% to 27541000.0 in 2023, then rose by 10.97% to 24519000.0 in 2024, then gained by 9.17% to 22271000.0 in 2025, then dropped by 13.45% to 25266000.0 in 2026.
• Per Business Quant, the three latest FHTX Cash from Operations figures stand at 25266000.0 (Q1 2026), 22271000.0 (Q4 2025), and 18860000.0 (Q3 2025).